Research programme: Hsp20 modulators - Prolexys
Alternative Names: Hsp20 modulators research programme - ProlexysLatest Information Update: 16 Jul 2016
At a glance
- Originator Prolexys Pharmaceuticals
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Erectile dysfunction; Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA